Ipsen Publishes Its 2017 Registration Document
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its 2017 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 23 March 2018 and registered under the number D.18-0180.
The document is available on the company’s website: www.ipsen.com and on the AMF’s website: www.amf-france.org. Copies are also available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France.
The following documents are incorporated into the 2017 Registration Document:
- Annual Financial Report;
- Board of Directors’ Report on corporate governance;
- Information relating to the fees paid to the Statutory Auditors.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Ipsen Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2017 Registration Document available on its website (www.ipsen.com).
Ian Weatherhead, +44 (0) 7584230549
Vice President Corporate External Communication
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Senior Manager, Global External Communications
Eugenia Litz, +44 (0) 1753 627721
Vice-President, Investor Relations
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants23.4.2018 11:30 | Pressemelding
Biogen (Nasdaq: BIIB) today announced new findings detailing the benefits that SPINRAZA® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as increased survival for the most severely affected. These findings are based on interim results from the SHINE open-label extension study and an analysis of SPINRAZA’s effects on mobility and fatigability in later-onset participants from the CS2/CS12 studies. The research will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 21-27, 2018, in Los Angeles, California. “These results reinforce SPINRAZA’s unprecedented and compelling efficacy across a broad range of SMA populations, enabling patients to improve mobility and motor function – and, for the most severely affected, increase their chances of survival,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “We look for
Country Leaders Inspired by ABB’s Breakthrough E-Mobility Technologies23.4.2018 11:06 | Pressemelding
The two leaders, along with ABB CEO Ulrich Spiesshofer, were shown a demonstration of the company’s new high power fast charging solution: the Terra HP EV charging station with a power output of up to 350 kW recharges a car battery in just eight minutes for 200 km reach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005618/en/ From left to right: German Chancellor Angela Merkel, Mexican President Enrique Peña Nieto, ABB CEO Ulrich Spiesshofer, First Lady Mrs. Angélica Rivera, Managing Director of ABB Germany Hans-Georg Krabbe, Managing Director of ABB Mexico Vicente Magana (Photo: Business Wire) “This high-power fast charger provides electric vehicles with up to seven times more range in the same charging time than with previous models,” Spiesshofer said. “Together with our comprehensive ABB AbilityTM digital offering, we easily connect chargers to back offices, payment platforms or smart grid systems and offer our cu
Panasonic Launches Off-grid Solutions Projectto Mark Its Centenary23.4.2018 10:07 | Pressemelding
Panasonic Corporation announced it has kicked off a project for people living in off-grid areas that combines educational activities to promote understanding of electricity and provision of the company’s related products. The Off-grid Solutions Project is part of Panasonic’s corporate social responsibility initiatives, celebrating the centennial of the company’s founding this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005551/en/ Power Supply Station installed in Indonesia as part of the project (West Kalimantan) (Photo: Business Wire) This new initiative aims to support the creation of a sustainable society where each individual living without access to the power grid can lead an independent life. Panasonic will donate its products such as solar generation and storage systems, provide education and technical training to cultivate human resources, and help develop local business models taking advantage of elec
CORRECTING and REPLACING FlexTrade Launches FlexNOW Execution Management System (EMS)23.4.2018 08:56 | Pressemelding
Quote in sixth paragraph should be attributed to Lucas Howarth, Fund Manager at Wesleyan (sted of Chris Beton, CTO/CRO at Everett Capital Advisors). The corrected release reads: FLEXTRADE LAUNCHES FLEXNOW EXECUTION MANAGEMENT SYSTEM (EMS) – One-Click Deployment System for Hedge Funds and Mini-Primes – – MiFID II Compliant Trading for Equities, Futures & Options – FlexTrade (@FlexTrade) today announced the official release of FlexNOW, an out-of-the-box, broker neutral EMS to address the needs of hedge funds and mini-primes who require a streamlined, multi-asset trading system at the click of a button. Multi-Asset, MiFID II Compliant Trading -- Designed to handle trading for equities, futures and options, FlexNOW is MiFID II compliant; provides connectivity to leading market data providers; easily integrates with any order management system (OMS) via FIX and API; and comes with its own built-in transaction cost analysis functionality. Easy Installation -- According to Rhyd Lewis, FlexNOW
FlexTrade Launches FlexNOW Execution Management System (EMS)23.4.2018 08:00 | Pressemelding
FlexTrade (@FlexTrade) today announced the official release of FlexNOW, an out-of-the-box, broker neutral EMS to address the needs of hedge funds and mini-primes who require a streamlined, multi-asset trading system at the click of a button. Multi-Asset, MiFID II Compliant Trading -- Designed to handle trading for equities, futures and options, FlexNOW is MiFID II compliant; provides connectivity to leading market data providers; easily integrates with any order management system (OMS) via FIX and API; and comes with its own built-in transaction cost analysis functionality. Easy Installation -- According to Rhyd Lewis, FlexNOW Product Manager at FlexTrade UK, FlexNOW’s zero-touch onboarding and installation process gets clients up and running in a matter of minutes. “By combining the one-click installation process with secure, online connectivity, we have greatly reduced the on-boarding lead time for customers,” said Lewis. Streamlined Trading Workflows -- “We developed FlexNOW based o
Limited Edition Skechers D’Lites & Toei Animation One Piece Collection to Launch in Europe23.4.2018 07:00 | Pressemelding
After initially launching in Asia and with an upcoming debut in the United States and Canada, SKECHERS USA, Inc. (NYSE:SKX) is extending its popular anime collaboration to Europe as well with the launch of Skechers X One Piece. The colorful collection unites Toei Animation’s popular anime series with Skechers D’Lites, one of the footwear company’s original styles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005239/en/ Skechers launches limited edition One Piece collection in Europe (Photo: Business Wire) “Pairing the iconic long-running anime series One Piece with one of our top heritage styles resonated with our consumers in South Korea and China who have been driving trends for the past few years,” began Michael Greenberg, president of Skechers. “And now fashion moves at light speed, so as influencers around the world had already been embracing Skechers D’Lites and the chunky sneaker trend, we started to see style